The Arguments WHAT THE INDUSTRY ARGUES Supporters point to evidence that the No Surprises Act is working as intended. According to a report cited by Techtarget, there has been greater in-network participation since the law took effect, suggesting that providers are increasingly joining insurance networks rather than remaining out-of-network. Proponents argue this directly reduces the…
The Arguments WHAT THE INDUSTRY ARGUES Some argue that higher US drug prices reflect the cost of pharmaceutical innovation and research, and that government price negotiations or reference pricing could reduce costs for American consumers. The Trump administration claimed it was securing deals with pharmaceutical companies to bring prices down, asserting Americans would pay ‘the…
The United States pays more for prescription drugs than any other country in the world — often two to ten times more for the same medication. The reasons are structural, layered, and deeply contested. This guide explains the full chain from drug manufacturer to pharmacy counter, who profits at each step, and what recent policy…